Form 4 for FDMT 4D Molecular Therapeutics, Inc.
Accepted 2026-08-21 16:06:38 ET · period of report 2026-08-19 · accession 0001193125-26-361096 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DT | 2026-08-21 16:06 | 2026-08-19 | FDMT | Kirn David | See Remarks, Dir | M - OptEx | $4.14 | +50.0K | 894.9K | +6% | +$207.0K |
| DMT | 2026-08-21 16:06 | 2026-08-19 | FDMT | Kirn David | See Remarks, Dir | S - Sale+OE | $15.75 | -69.1K | 825.8K | -8% | -$1.09M |
| DT | 2026-08-21 16:06 | 2026-08-19 | FDMT | Kirn David | See Remarks, Dir | M - OptEx | $0.00 | -50.0K | 217.5K | -19% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-08-19 | M | A | 50,000 | $4.14 | 894,895 | D | — | — | (F1) Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on January 9, 2026. |
| 2 | Common | Common Stock | 2026-08-19 | S | D | 43,149 | $15.36 | 851,746 | D | — | — | (F1) Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on January 9, 2026. (F2) The transaction was executed in multiple trades in prices ranging from $14.91 to $15.84, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. |
| 3 | Common | Common Stock | 2026-08-19 | S | D | 25,927 | $16.42 | 825,819 | D | — | — | (F1) Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on January 9, 2026. (F3) The transaction was executed in multiple trades in prices ranging from $15.97 to $16.65, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. |
| 4 | Derivative | Stock Option (Right to Buy) | 2026-08-19 | M | D | 50,000 | $0.00 | 217,500 | D | $4.14 · — to 2035-03-05 | 50,000 Common Stock | (F1) Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on January 9, 2026. (F4) The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of March 6, 2025 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company. |